BetterLife Pharma Inc. announced it has completed its 4-week oral BETR-001 GLP toxicology study in animals. The study demonstrated that BETR-001's repeated dosing for 4 weeks is very well-tolerated. The study findings support a broad therapeutic window for the use of BETR-001 in humans.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0946 USD | +3.41% | +13.43% | +97.08% |
May. 14 | BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001 | CI |
May. 03 | BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+97.08% | 10.98M | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.23% | 22.28B | |
-5.61% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- BETRF Stock
- News BetterLife Pharma Inc.
- BetterLife Pharma Inc. Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001